share_log

8-K: Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance

8-K: Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance

8-K:Biote公佈2024年第二季度財務業績程序收入增長連續加速 BioTerx的推出步入正軌,並計劃進一步擴張。管理層重申了2024年的財務指導
美股SEC公告 ·  2024/08/08 13:48
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息